The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

Behavioural Brain Research

Volumn 237, Issue 1, 2013, Pages 164-171

  McIntyre, Roger S ^a,b,c   Powell, Alissa M ^c   Kaidanovich Beilin, Oksana ^d   Soczynska, Joanna K ^b,c   Alsuwaidan, Mohammad ^c   Woldeyohannes, Hanna O ^c   Kim, Ashley S ^c   Gallaugher, L Ashley ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cognition; GLP 1; Incretins; Mood disorders; Neuroprotection

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LIRAGLUTIDE; PLACEBO;

ALZHEIMER DISEASE; BODY WEIGHT DISORDER; CELL PROTECTION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MOOD DISORDER; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; TREATMENT OUTCOME;

COGNITION DISORDERS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MOOD DISORDERS; NEUROPROTECTIVE AGENTS;

EID: 84867435685     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.09.021     Document Type: Review

References (66)

1. Ketter T.A. Diagnostic features, prevalence, and impact of bipolar disorder. Journal of Clinical Psychiatry 2010, 71(June (6)):e14.
2. Beach S.R., Whisman M.A. Affective disorders. Journal of Marital and Family Therapy 2012, 38(January (1)):201-219.
3. Millan M.J., Agid Y., Brune M., Bullmore E.T., Carter C.S., Clayton N.S., et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery 2012, 11(2):141-168.
4. Hill S.K., Bishop J.R., Palumbo D., Sweeney J.A. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Review of Neurotherapeutics 2010, 10(January (1)):43-57.
5. den H.T., Vermeer S.E., van Dijk E.J., Prins N.D., Koudstaal P.J., Hofman A., et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003, 46(December (12)):1604-1610.
6. Convit A., De Leon M.J., Tarshish C., De S.S., Tsui W., Rusinek H., et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiology of Aging 1997, 18(March (2)):131-138.
7. Musen G., Lyoo I.K., Sparks C.R., Weinger K., Hwang J., Ryan C.M., et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006, 55(February (2)):326-333.
8. Porter R.J., Gallagher P., Thompson J.M., Young A.H. Neurocognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry 2003, 182(March):214-220.
9. Gispen W.H., Biessels G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends in Neurosciences 2000, 23(November (11)):542-549.
10. McIntyre R.S., Danilewitz M., Liauw S.S., Kemp D.E., Nguyen H.T., Kahn L.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. Journal of Affective Disorders 2010, 126(November (3)):366-387.
11. McIntyre R.S., Soczynska J.K., Konarski J.Z., Woldeyohannes H.O., Law C.W., Miranda A., et al. Should depressive syndromes be reclassified as metabolic syndrome type II?. Annals of Clinical Psychiatry 2007, 19(October (4)):257-264.
12. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. American Journal of Medicine 2011, 124(January (1 Suppl.)):S3-S18.
13. Tahrani A.A., Bailey C.J., Del P.S., Barnett A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378(July (9786)):182-197.
14. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(September (18)):8641-8645.
15. Green B.D., Gault V.A., Flatt P.R., Harriott P., Greer B., O'Harte F.P. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Archives of Biochemistry and Biophysics 2004, 428(August (2)):136-143.
16. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379(January (6560)):69-72.
17. Navarro M., Rodriquez de F.F., Alvarez E., Chowen J.A., Zueco J.A., Gomez R., et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. Journal of Neurochemistry 1996, 67(November (5)):1982-1991.
18. Goke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. European Journal of Neuroscience 1995, 7(November (11)):2294-2300.
19. Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Penicaud L., et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008, 57(October (10)):2577-2587.
20. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26(October (10)):2929-2940.
21. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine 2003, 9(September (9)):1173-1179.
22. McClean P.L., Gault V.A., Harriott P., Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. European Journal of Pharmacology 2010, 630(March (1-3)):158-162.
23. Holscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitamins and Hormones 2010, 84:331-354.
24. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(May (6)):2131-2157.
25. Cefalu W.T. Evolving treatment strategies for the management of type 2 diabetes. American Journal of the Medical Sciences 2012, 343(January (1)):21-26.
26. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44(September (9)):1126-1131.
27. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Practice and Research. Clinical Endocrinology and Metabolism 2007, 21(December (4)):497-516.
28. Christensen M., Knop F.K. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide?. Current Diabetes Reports 2010, 10(April (2)):124-132.
29. Quintanilla-Garcia C., Zuniga-Guajardo S. The incretin effect and type 2 diabetes. Revista Medica del Instituto Mexicano del Seguro Social 2010, 48(September (5)):509-520.
30. Alvarez E., Martinez M.D., Roncero I., Chowen J.A., Garcia-Cuartero B., Gispert J.D., et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Journal of Neurochemistry 2005, 92(February (4)):798-806.
31. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. Journal of Comparative Neurology 1999, 403(January (2)):261-280.
32. D'Alessio D.A., Sandoval D.A., Seeley R.J. New ways in which GLP-1 can regulate glucose homeostasis. Journal of Clinical Investigation 2005, 115(December (12)):3406-3408.
33. Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., Seeley R.J. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008, 57(August (8)):2046-2054.
34. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. American Journal of Physiology 1999, 277(August (2 Pt 2)):R582-R590.
35. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. Journal of Clinical Investigation 2002, 110(July (1)):43-52.
36. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. Journal of Pharmacology and Experimental Therapeutics 2002, 302(September (3)):881-888.
37. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. Journal of Molecular Neuroscience 2002, 18(February (1-2)):7-14.
38. Yamamoto H., Kishi T., Lee C.E., Choi B.J., Fang H., Hollenberg A.N., et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. Journal of Neuroscience 2003, 23(April (7)):2939-2946.
39. Dogrukol-Ak D., Tore F., Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Current Pharmaceutical Design 2004, 10(12):1325-1340.
40. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. International Journal of Obesity and Related Metabolic Disorders 2003, 27(March (3)):313-318.
41. McGovern S.F., Hunter K., Holscher C. Effects of the glucagon-like polypeptide-1 analogue (Val(8))GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Research 2012, 1473(September):204-213.
42. Hunter K., Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience 2012, 13:33.
43. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. Journal of Neuroscience Research 2003, 72(June (5)):603-612.
44. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(January (4)):1285-1290.
45. Kimura R., Okouchi M., Fujioka H., Ichiyanagi A., Ryuge F., Mizuno T., et al. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009, 162(September (4)):1212-1219.
46. Biswas S.C., Buteau J., Greene L.A. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochemical Research 2008, 33(September (9)):1845-1851.
47. McClean P.L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. Journal of Neuroscience 2011, 31(April (17)):6587-6594.
48. Gengler S., McClean P.L., McCurtin R., Gault V.A., Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiology of Aging 2012, 33(February (2)):265-276.
49. Gilman C.P., Perry T., Furukawa K., Grieg N.H., Egan J.M., Mattson M.P. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. Journal of Neurochemistry 2003, 87(December (5)):1137-1144.
50. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. Journal of Alzheimer's Disease 2010, 19(4):1205-1219.
51. D'Amico M., Di F.C., Marfella R., Abbatecola A.M., Ferraraccio F., Rossi F., et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Experimental Gerontology 2010, 45(March (3)):202-207.
52. Oka J.I., Goto N., Kameyama T. Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 1999, 10(June (8)):1643-1646.
53. Wang X.H., Li L., Holscher C., Pan Y.F., Chen X.R., Qi J.S. Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 2010, 170(November (4)):1239-1248.
54. Gault V.A., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. European Journal of Pharmacology 2008, 587(June (1-3)):112-117.
55. Porter D.W., Kerr B.D., Flatt P.R., Holscher C., Gault V.A. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes, Obesity and Metabolism 2010, 12(October (10)):891-899.
56. Gault V.A., Porter W.D., Flatt P.R., Holscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. International Journal of Obesity (London) 2010, 34(August (8)):1341-1344.
57. Abbas T., Faivre E., Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behavioural Brain Research 2009, 205(December (1)):265-271.
58. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. Journal of Pharmacology and Experimental Therapeutics 2002, 300(March (3)):958-966.
59. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. Journal of Neuroscience Research 2008, 86(February (2)):326-338.
60. Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. Journal of Neuroscience Research 2011, 89(April (4)):481-489.
61. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Experimental Neurology 2007, 203(February (2)):293-301.
62. Belsham D.D., Fick L.J., Dalvi P.S., Centeno M.L., Chalmers J.A., Lee P.K., et al. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB Journal 2009, 23(December (12)):4256-4265.
63. Stranahan A.M., Norman E.D., Lee K., Cutler R.G., Telljohann R.S., Egan J.M., et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008, 18(11):1085-1088.
64. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. European Journal of Pharmacology 2011, 650(January (1)):249-255.
65. Iwai T., Suzuki M., Kobayashi K., Mori K., Mogi Y., Oka J. The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neuroscience Research 2009, 64(May (1)):67-74.
66. Kinzig K.P., D'Alessio D.A., Herman J.P., Sakai R.R., Vahl T.P., Figueiredo H.F., et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. Journal of Neuroscience 2003, 23(July (15)):6163-6170.